NewEdge Advisors’s BridgeBio Pharma BBIO Stock Holding History

NewEdge Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,743	Closed	-$286K	–	4152
2025 Q4	$286K	Buy	+3,743	New	+$246K	﹤0.01%	2341

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NewEdge Advisors's BBIO Position: Q1 2026 in Review

NewEdge Advisors sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 3,743 shares — an estimated $286K sold.

NewEdge Advisors first reported a position in BBIO in Q4 2025 and held it in 1 quarter. The position peaked at $286K in Q4 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

NewEdge Advisors reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 3,743 BridgeBio Pharma shares in Q1 2026, an estimated $286K.
NewEdge Advisors first reported a position in BridgeBio Pharma in Q4 2025 and held it in 1 quarter.
NewEdge Advisors's BridgeBio Pharma position peaked at $286K in Q4 2025.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.